Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Novogen Limited NVGN

Healthcare Drug Manufacturers - Specialty & Generic
"Novogen Ltd is a pharmaceutical drug development based on a simple benzopyran chemical structure. It is an emerging oncology-focused biotechnology company that develops anti-cancer drugs."

Recent & Breaking News (NDAQ:NVGN)

31 Stocks Moving In Monday's Mid-Day Session

Benzinga.com  November 6, 2017

Australian cancer specialists may hold key to next advancement in ovarian cancer treatment

PR Newswire Asia August 30, 2017

GDC-0084 Progress Update: On Track for Phase II Commencement in 2017

PR Newswire Asia August 22, 2017

Board Review of Business Operations and Governance

PR Newswire August 14, 2017

Board Review of Business Operations and Governance

PR Newswire Asia August 13, 2017

Progress Update on Cantrixil(TM) (TRXE-002-1) Development

PR Newswire August 7, 2017

Progress Update on Cantrixil(TM) (TRXE-002-1) Development

PR Newswire Asia August 6, 2017

12 Biggest Mid-Day Losers For Thursday

Benzinga.com  April 6, 2017

Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

PR Newswire Europe Non Regulatory March 10, 2017

Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure

PR Newswire Asia March 9, 2017

Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program

PR Newswire March 6, 2017

Must Watch Stocks for October 31, 2016

Benzinga.com  October 31, 2016

Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma

PR Newswire Asia October 30, 2016

Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma

PR Newswire October 30, 2016

Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma

PR Newswire October 30, 2016

Novogen Acquires Privately-held Glioblast for AU$2.1M in Cash, Stock, Plus Milestones

Benzinga.com  October 30, 2016

Conversion of Convertible Notes

PR Newswire Asia September 14, 2016

Must Watch Stocks for September 12, 2016

Benzinga.com  September 12, 2016

US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer

PR Newswire Asia September 11, 2016

Novogen Announces FDA Approves IND Application for Cantrixil in Ovarian Cancer

Benzinga.com  September 11, 2016